Biomatter

What Biomatter does

Biomatter is a synthetic biology company that uses generative AI to design novel enzymes from scratch for industrial applications. The company's core technology is the Intelligent Architecture™ platform, which enables de novo enzyme design across a broad range of enzyme families including glycosyltransferases, polymerases, reductases, lyases, proteases, and protein binders. Biomatter claims to be the first team to develop fully functional enzymes using generative AI, with foundational research published in Nature Machine Intelligence.

The company operates as a B2B partnership-driven enterprise, collaborating with global industry leaders such as Thermo Fisher Scientific, BASF, Cargill, Neogen, and Kirin to develop custom enzymes for applications in healthcare, agriculture, food, and chemical manufacturing. Revenue is generated through development fees, milestone payments, IP licensing, and outcome-based pricing tailored to each unique enzyme project. The company offers end-to-end services from initial concept through design, experimental validation, scale-up, and enzyme production.

Founded in 2019 and headquartered in Vilnius, Lithuania (with a US corporate entity, BIOMATTER INC.), Biomatter is venture-backed, having raised €6.5 million in seed funding in August 2024 led by Inventure VC and UVC Partners.

Name

Biomatter

Legal name

BIOMATTER INC.

Website

https://biomatter.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Biomatter is a synthetic biology company that uses its proprietary Intelligent Architecture™ generative AI platform to design novel enzymes from scratch for industrial applications, partnering with global enterprises in healthcare, agriculture, food, and chemicals.

Ownership category

akta.pro rank

Product category

Generative AI Enzyme Design

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAAAIAC

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAJAF

Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)

Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

SECONDARYHLAAAKAF

Process Development & Tech Transfer Services (upstream/downstream)

Healthcare & Life Sciences/Biotechnology & Biologics/Biomanufacturing Services

SECONDARYAFAJAIAF

Protein Processing Enzymes (Meat/Seafood/Plant)

Agriculture & Food Production/Food Ingredients & Additives/Enzymes & Processing Aids (Food Enzymes, Clarifying/Filtering Aids)

Keywords

• Generative enzyme design
• AI protein engineering
• De novo enzymes
• Synthetic biology platform
• Enzyme development services

Headquarters

HQ city

Vilnius

HQ country

Lithuania

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Enzyme Development Partnerships: Biomatter partners with leading companies to develop custom enzymes for specific industrial applications. Revenue is generated through development fees, milestone payments, and outcome-based pricing tailored to each enzyme project.
2. IP Licensing: The company licenses its proprietary enzyme designs and the Intelligent Architecture platform technology to partners, generating licensing and royalty revenue.
3. Strategic Collaboration Agreements: Long-term co-development and strategic collaboration arrangements with global partners, potentially including upfront fees, research funding, and commercial milestones.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Biomatter operates the Intelligent Architecture™ platform, an AI-first generative platform that designs novel enzymes from scratch for industrial applications. The company partners with global enterprises to deliver end-to-end enzyme development—from initial concept, computational design, and experimental validation through scale-up and enzyme production—via co-development, IP licensing, and strategic collaboration arrangements.

Product overview

Biomatter offers a unified platform-plus-services model centered on the Intelligent Architecture™ platform, which enables generative AI-driven de novo enzyme design. The platform supports creation of diverse enzyme types including glycosyltransferases, polymerases, reductases, lyases, proteases, and others. Services include end-to-end enzyme development from concept through scale-up and production, with flexible partnership models and outcome-based pricing tailored to each project.

Differentiator

Problem solved

Functional benefit

Products and services

• Intelligent Architecture™ Platform AI-first platform that enables near-perfect control over enzyme design and supports de novo creation of novel enzymes for previously impossible technical applications, from concept through production. Used by enterprise partners across biotech, agriculture, food, and chemical manufacturing.
• Enzyme Design Services End-to-end enzyme development services covering concept, design, experimental validation, scale-up, and enzyme production for stand-alone enzymes and multi-enzyme systems used in chemical manufacturing. Delivered to enterprise partners under co-development or strategic collaboration agreements.

Quantifiable outcome

• Enzyme delivery in weeks rather than years
• +1 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature14 records

Partnerships

Five partnerships are on record, tiered core partner.

• Thermo Fisher Scientificcore partnerStrategic or Co-development PartnerThermo Fisher Scientific is a global leader in laboratory reagents and life sciences. Biomatter partners with Thermo Fisher for enzyme development, leveraging the Intelligent Architecture platform to design novel enzymes for industrial biotechnology applications.
• BASFcore partnerStrategic or Co-development PartnerBASF, a leading global chemical company, collaborates with Biomatter on enzyme design for chemical manufacturing and agricultural applications, utilizing generative AI for novel enzyme development.
• Neogencore partnerStrategic or Co-development PartnerNeogen, a company specializing in animal genomics and food safety, partners with Biomatter for novel enzyme development in food safety and animal health applications.
• Cargillcore partnerStrategic or Co-development PartnerCargill, a global food and ingredient company, collaborates with Biomatter on enzyme design with applications in infant nutrition and food ingredient manufacturing.
• Kirincore partnerStrategic or Co-development PartnerKirin, a Japanese beverages and food ingredients company, partners with Biomatter for enzyme development in food and beverage manufacturing applications.

Scale indicators3 records

Recent moves2 records

Expansion highlights5 records

Direct peers

• Cradle Bio: Cradle applies generative AI/ML to protein and enzyme design for industrial biotech, offering a design platform and partnerships with manufacturers. It is the closest direct competitor to Biomatter in terms of technology stack, target customer profile, and GTM motion.
• Profluent Bio: Profluent develops generative AI models for protein design with applications including enzymes and therapeutics. It competes for the same enterprise design partnerships and shares the AI-first protein engineering thesis with Biomatter.
• Generate Biomedicines: Generate Biomedicines uses generative AI to design novel protein therapeutics across modalities. While more therapeutics-focused, it is a direct competitor for AI-designed enzyme/protein partnerships in pharma and a benchmark for category valuations.
• Arzeda: Arzeda designs novel enzymes and metabolic pathways for industrial applications using computational protein design. It is a direct competitor in industrial enzyme design with a longer operating history and overlapping customer verticals (chemicals, food, consumer products).

Broad incumbents

• Codexis: Codexis is an established protein engineering company commercializing engineered enzymes for pharmaceuticals and industrial applications. It represents the legacy directed-evolution incumbent whose workflows Biomatter is positioning to disrupt.
• Ginkgo Bioworks: Ginkgo Bioworks is a large synthetic biology platform serving industrial biotech customers across food, agriculture, and chemicals. It competes for the same enterprise enzyme/bioprocess partnerships at much greater scale and capital intensity.
• Isomorphic Labs: Isomorphic Labs (Alphabet/DeepMind spin-out) applies AI to drug discovery and protein design. Although primarily therapeutics-focused, its AlphaFold-derived capabilities set the technical benchmark for AI-protein design and influence enterprise expectations.
• Novozymes (Novonesis): Novonesis (formerly Novozymes) is the world's largest industrial enzyme company. It is a broad incumbent that both competes for and partners on novel enzyme deployment across food, agriculture, and chemicals.

Emerging players

• EvolutionaryScale: EvolutionaryScale is developing frontier AI models for protein design with applications in biology and therapeutics. It is an emerging category peer that could compete for talent and customer mind-share in generative protein design.
• Bota Bio: Bota Bio applies AI and bioengineering to design and scale bioprocesses for chemicals and ingredients. It overlaps with Biomatter in industrial enzyme/bioprocess partnerships and AI-driven biomanufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomatter